ArticleTranslational cancer research2026
The prognostic value of log odds of positive lymph nodes in patients with resectable locally advanced gastric cancer following neoadjuvant therapy: results from the SEER database.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymph node status is a critical prognostic factor for locally advanced gastric cancer (LAGC), but the comparative value of different lymph node metrics after neoadjuvant chemotherapy (NACT) remains unclear. This study aims to evaluate and compare the prognostic utility of positive lymph nodes (pLNs), lymph node ratio (LNR), and the log odds of positive lymph nodes (LODDS) in patients with LAGC undergoing radical gastrectomy after NACT. Methods: A total of 1,976 patients from the Surveillance, Epidemiology, and End Results (SEER) database and a propensity score-matched (PSM) validation cohort of 69 Chinese patients were analyzed. A NACT-only subgroup (n=658) was evaluated to exclude radiotherapy effects. Prognostic value was assessed via Cox models, Kaplan-Meier curves, concordance indices (C-indices), and time-dependent receiver operating characteristic (ROC) analyses. Results: In the SEER cohort, LODDS >-2.02 and LNR >0.12 showed comparable hazard ratios (HRs) for overall survival (OS) and cancer-specific survival (CSS), both outperforming pLNs. LODDS demonstrated the highest prognostic accuracy (OS: C-index 0.671; CSS: 0.690). In the NACT-only subgroup, LODDS remained the strongest predictor (OS: HR =3.34; CSS: HR =3.69) with superior C-indices (OS: 0.718; CSS: 0.730). An independent Chinese validation cohort (n=69) preliminarily supported LODDS' prognostic strength (multivariable OS: HR =20.61, P=0.008; CSS: HR =14.58, P=0.02). Conclusions: LODDS provides modest but robust and supplementary prognostic value in LAGC patients treated with neoadjuvant therapy. Its integration into existing staging systems may enhance individualized risk stratification and guide clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.